Cosmos Health Inc.: financial statements

COSMNASDAQHealthcare · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Price

$2.87

November 19, 2026

What Ploutos Investor adds for Cosmos Health

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from 2013
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 1,325% since Aug 18, 2026, when the 10-Q these figures come from was filed ($0.21 then, $2.95 on Nov 18, 2026). The figures date from before that move.10-Q
  • The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+10.6% a year over 2 years

Line202320242025Average a year
Revenue $53M$54M$65M+10.6%
Cost of revenue $49M$50M$57M+8.2%
Gross profit $4.3M$4.3M$7.9M+34.7%
Operating income -$22M-$16M-$17M
Net income -$19M-$16M-$19M
Earnings per share -$2.15-$1.17-$0.63
Earnings per share, basic -$2.15-$1.17-$0.63
Margins
Gross margin 8.1%7.9%12.1%
Operating margin -40.9%-28.6%-25.6%
Net margin -34.7%-29.7%-29.3%

Financial statements

COSM's revenue, profits and cash flows from 2013 to 2022, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: Wholesale $51M, Nutraceuticals And Pharmaceuticals $2.3M, Pharmamanufacturing $344.7K, Other $0
  • 2024: Wholesale $52M, Nutraceuticals And Pharmaceuticals $2.0M, Pharmamanufacturing $865.4K, Other $0
  • 2025: Wholesale $59M, Nutraceuticals And Pharmaceuticals $4.3M, Pharmamanufacturing $1.7M, Other $1.2K
Segment202320242025Share 2025
Wholesale$51M$52M$59M91%
Nutraceuticals And Pharmaceuticals$2.3M$2.0M$4.3M6.5%
Pharmamanufacturing$344.7K$865.4K$1.7M2.6%
Other$0$0$1.2K0.0%

From the XBRL of 12 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$2.9M Due within 2 years$599.4K Leases0.0% Effective tax rate

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

When the debt falls due

Dec 31, 2025

Due within 2 years

$2.9M

Principal of loans and bonds falling due, from the annual report dated December 31, 2025, without leases and interest. The filing

  • 2026: $2.2M
  • 2027: $742.4K

Leases

Dec 31, 2025

Operating leases

$595.6K

Finance leases

$3.9K

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt.

Goodwill by segment

Dec 31, 2025

Total goodwill

$49.7K

The company does not state its goodwill by segment, at December 31, 2025. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

Other than debt, no claim large enough to list ranks ahead of the shares.

From the balance sheet of June 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. A line is listed when it is at least 0.5% of total assets, as there is no market value to compare with. A description of the balance sheet, not a valuation.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Jun 30, 2026, sales were +28.8% on the same quarter a year earlier, and receivables +22.0%. Inventory was -11.6%, against +28.7% for the cost of sales.

a year earlier 94 days
89 days
a year earlier 34 days
23 days

Balances at Jun 30, 2026 and Jun 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

The tax part is not shown: a figure it needs is missing from the company's structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Cosmos Health's filings show?

These are Cosmos Health's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about COSM's financials

Didn't find what you were looking for?

Ask us
How much revenue did COSM have in 2025?

Cosmos Health had revenue of $65M and net income of -$19M in fiscal 2025, a net margin of -29.3%.

How much debt does COSM have?

On December 31, 2025 Cosmos Health had total assets of $65M, debt of $6.0M and shareholders' equity of $18M.

How much free cash flow does COSM have?

In fiscal 2025 Cosmos Health had cash from operations of -$8.4M and spent $55.7K on capital expenditure, leaving -$8.5M of free cash flow.

Where are the figures from?

From Cosmos Health Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.